Reaffirmed: Jazz Pharmaceuticals (NASDAQ:JAZZ) “Buy” Rating Reconfirmed by Analysts at B. Riley FBR; $190 Target in Place

November 9, 2018 - By Ash

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment increased to 1.52 in 2018 Q2. Its up 0.50, from 1.02 in 2018Q1. It is positive, as 25 investors sold Jazz Pharmaceuticals plc shares while 88 reduced holdings. 79 funds opened positions while 93 raised stakes. 54.43 million shares or 4.78% more from 51.95 million shares in 2018Q1 were reported.

Strs Ohio holds 216,985 shares. Maverick Capital holds 0.08% or 41,910 shares. State Street Corp reported 0.02% stake. Banced Corp reported 0.94% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Acadian Asset Ltd Llc invested in 164,525 shares. Globeflex Cap L P owns 3,106 shares or 0.11% of their US portfolio. Citigroup accumulated 39,858 shares or 0.01% of the stock. Utah-based Utah Retirement has invested 0.04% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Essex Management Co Lc holds 0.43% or 19,995 shares. Avalon Advsr Lc has 0.1% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 19,781 shares. Mckinley Capital Mgmt Ltd Llc Delaware holds 0.02% or 1,708 shares in its portfolio. Gateway Invest Advisers Limited Co holds 28,131 shares. Prudential Financial holds 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 1,970 shares. 11,872 are held by Public Employees Retirement Association Of Colorado. Moreover, Legal & General Public Ltd Co has 0.03% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 241,295 shares.

Since May 11, 2018, it had 0 insider buys, and 17 sales for $5.27 million activity. The insider MILLER MICHAEL PATRICK sold $35,306. On Monday, May 14 the insider Young Matthew P. sold $233,789. 10,130 Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares with value of $1.71M were sold by ENRIGHT PATRICK G. 3,760 shares were sold by WILSON KAREN J, worth $620,400. Gray Peter sold 715 shares worth $126,277. $116,563 worth of stock was sold by O’Keefe Kenneth W on Thursday, August 9.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reaffirmed

Equity analysts at B. Riley FBR now has a $190 target on Jazz Pharmaceuticals (NASDAQ:JAZZ). B. Riley FBR and their recent target suggests a potential upside of 33.62 % from the company’s last stock close price. The rating has been revealed in an analyst report on Thursday morning.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 6 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Jazz Pharmaceuticals has $21900 highest and $190 lowest target. $200’s average target is 40.66% above currents $142.19 stock price. Jazz Pharmaceuticals had 8 analyst reports since May 10, 2018 according to SRatingsIntel. Citigroup maintained the stock with “Buy” rating in Tuesday, July 10 report. FBR Capital maintained the stock with “Buy” rating in Monday, June 25 report. As per Thursday, May 10, the company rating was maintained by FBR Capital. On Wednesday, August 8 the stock rating was maintained by BMO Capital Markets with “Outperform”. The firm has “Buy” rating given on Thursday, November 8 by FBR Capital. On Wednesday, July 11 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. RBC Capital Markets maintained it with “Buy” rating and $19400 target in Friday, June 1 report. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, August 8.

The stock increased 1.27% or $1.78 during the last trading session, reaching $142.19. About 1.74 million shares traded or 241.12% up from the average. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has risen 6.65% since November 9, 2017 and is uptrending. It has underperformed by 8.97% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $8.59 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 20.06 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

More important recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Nasdaq.com which released: “Why Jazz Pharmaceuticals plc Stock Is Slumping Today” on November 07, 2018, also Benzinga.com published article titled: “88 Biggest Movers From Yesterday”, Seekingalpha.com published: “FDA OKs expanded use for Jazz Pharma’s Xyrem” on October 29, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was released by: Streetinsider.com and their article: “Jazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital” with publication date: November 07, 2018.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>